Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
Status:
RECRUITING
Trial end date:
2027-11-13
Target enrollment:
Participant gender:
Summary
For patients with metastatic gastric cancer, the efficacy of current standard treatments outlined in the guidelines is far from meeting the clinical demand. This study aims to explore the efficacy and safety of trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab as a novel third-line or later-line therapy for metastatic gastric cancer patients.
Phase:
PHASE2
Details
Lead Sponsor:
LIN YANG
Treatments:
Bevacizumab camrelizumab tipiracil Trifluridine trifluridine tipiracil drug combination